Zobrazeno 1 - 10
of 107
pro vyhledávání: '"Jeppe Sturis"'
Autor:
František Hubálek, Christian N. Cramer, Hans Helleberg, Eva Johansson, Erica Nishimura, Gerd Schluckebier, Dorte Bjerre Steensgaard, Jeppe Sturis, Thomas B. Kjeldsen
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Insulin icodec is a once-weekly insulin analogue that has a long half-life of approximately 7 days, making it suitable for once weekly dosing. The Insulin icodec molecule was developed based on the hypothesis that lowering insulin receptor a
Externí odkaz:
https://doaj.org/article/ade547bc0d3d4366b9971dbb3db3a7f1
Autor:
Thomas Sparre, Laura Hammershøy, Dorte Bjerre Steensgaard, Jeppe Sturis, Per Vikkelsøe, Antonino Azzarello
Publikováno v:
Journal of Diabetes Science and Technology. 17:290-301
Background: Insulin treatment is an essential hormone replacement therapy for the survival of people with type 1 diabetes and is often used for treatment in type 2 diabetes, particularly as the disease progresses. Advances in insulin therapy have bee
Autor:
Thomas Hoeg-Jensen, Rita Slaaby, Thomas Kruse, Christian Lehn Brand, Jeppe Sturis, Christian Fledelius, Peter Nielsen, Erica Nishimura, Alice Madsen, Lennart Lykke, Kim Halskov, Simona Koscova, Vladaslav Kotek, Anthony Davis, Robert Tromans, Michael Tomsett, Guillem Penuelas-Haro, Daniel J. Leonard, Michael Orchard, Andy Chapman, Gaetano Invernizzi, Eva Johansson, Daniele Granata, Bo Hansen, Thomas Pedersen, Jonas Kildegaard, Karen Pedersen, Hanne Refsgaard, Lene Alirangis, Johannes Fels, Anita Neutzsky-Wulff, Per Sauerberg
The risk of inducing hypoglycaemia (low blood glucose) constitutes the main challenge associated with insulin therapy for diabetes. Insulin doses must be adjusted to ensure blood glucose values within normal range, but matching insulin doses to fluct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9f11fc10aa8b4da1245021a1cf15e84
https://doi.org/10.21203/rs.3.rs-2882397/v1
https://doi.org/10.21203/rs.3.rs-2882397/v1
Publikováno v:
Diabetes Technology & Therapeutics
Background: In the onset 5 trial, fast-acting insulin aspart (faster aspart) was noninferior to insulin aspart (IAsp) for change from baseline glycated hemoglobin at 16 weeks, when used in continuous subcutaneous insulin infusion by participants with
Autor:
Hanne Haahr, Thomas Kjeldsen, Peter Kurtzhals, Peter Madsen, Erica Nishimura, Thomas Hoeg-Jensen, Jeppe Sturis, Eva Johansson
Publikováno v:
Trends in Pharmacological Sciences. 42:620-639
The life-saving discovery of insulin in Toronto in 1921 is one of the most impactful achievements in medical history, at the time being hailed as a miracle treatment for diabetes. The insulin molecule itself, however, is poorly amenable as a pharmaco
Autor:
MILLE KRONBORG LYHNE, KATHRIN HINZ, ANDREAS VEGGE, JEPPE STURIS, JONAS KILDEGAARD, ULRIK PEDERSEN-BJERGAARD, LISBETH HØIER OLSEN
Publikováno v:
Diabetes. 71
Hypoglycemia is a common adverse effect of insulin treatment in people with diabetes and recurrent episodes can alter counter regulation, ultimately increasing the risk of severe hypoglycemic episodes. The aim of this study was to investigate the eff
Autor:
Benyamin, Grosman, Di, Wu, Neha, Parikh, Anirban, Roy, Gayane, Voskanyan, Natalie, Kurtz, Jeppe, Sturis, Ohad, Cohen, Magnus, Ekelund, Robert, Vigersky
Publikováno v:
Computer methods and programs in biomedicine. 205
Medtronic has developed a virtual patient simulator for modeling and predicting insulin therapy outcomes for people with type 1 diabetes (T1D). An enhanced simulator was created to estimate outcomes when using the MiniMedSixty-seven participants' PK
Autor:
Jeppe Sturis, Natalie Kurtz, Magnus Ekelund, Gayane Voskanyan, Robert A. Vigersky, Benyamin Grosman, Ohad Cohen, Neha J. Parikh, Anirban Roy, Di Wu
Publikováno v:
Computer Methods and Programs in Biomedicine. 205:106087
Introduction Medtronic has developed a virtual patient simulator for modeling and predicting insulin therapy outcomes for people with type 1 diabetes (T1D). An enhanced simulator was created to estimate outcomes when using the MiniMedTM 670G system w
Autor:
Hanne H. F. Refsgaard, Stephen T. Buckley, Jeppe Sturis, Svend Ludvigsen, Torben Seested, Susanne Hostrup, Ulla Ribel, Niels Rode Kristensen, Helle Birk Olsen, Claus Bekker Jeppesen, Rasmus H. Nielsen, Jonas Kildegaard, Gro Klitgaard Povlsen, Kristian Moss Bendtsen
Publikováno v:
Pharmaceutical Research
Purpose Fast-acting insulin aspart (faster aspart) is a novel formulation of insulin aspart containing two additional excipients: niacinamide, to increase early absorption, and L-arginine, to optimize stability. The aim of this study was to evaluate
Autor:
Torben Laursen, Ole Skyggebjerg, Charlotte A. Ihlo, Jørgen S. Christiansen, Torsten Lauritzen, Jeppe Sturis
Publikováno v:
Diabetic Medicine. 28:230-236
Diabet. Med. 28, 230–236 (2011) Abstract Aims To study the pharmacokinetics and pharmacodynamics of three different modes of insulin infusion delivered by means of an insulin pump: subcutaneous bolus insulin injection once an hour, continuous subcu